Dr. Gunther Krumpl Chief Corporate Development Officer | Board Member

"AOP Orphan having international expertise in pharmaceutical and clinical development as well as distribution and marketing of drugs in the rare disease area offers flexible solutions for in- and out-licensing partnerships."

Personal Data Sheet

Dr. Gunther Krumpl habilitated from the University of Vienna’s Medical Faculty and Institute of Pharmacology in 1990. His academic career spans over thirty years where he worked as Professor and Lecturer at the University of Vienna within the Institute of Pharmacology and the Department of Anaesthesiology and Intensive Care specialising in the fields of Cardiovascular Pharmacology, CNS Pharmacology, Muscle relaxants and Addiction. Business wise he worked for Bayer-, Wellcome-, Glaxo- and Chiesi-Pharmaceuticals and received a commercial education at the London Business School.Dr Krumpl has published more than 50 articles in various leading academic journals and has given more than 100 lectures at international congresses. His contributions to academia have been recognized with the Hoechst Prize and the Prize of the Austrian Chamber of Doctors. In 1995 he co-founded Torrex Pharma GmbH and managed it successfully until its sale to Chiesi Pharmaceuticals in 2001. Over this period Dr Krumpl gained extensive experience in business development, commercial expansion and mergers and acquisitions. At AOP Orphan he worked as a consultant for R&D projects and specifically counselled the company on the successful Landiolol-Programm. He has now been elected as a Board Member and Chief Corporate Development Officer at AOP Orphan.